Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Kleoniki Apostolidou"'
Autor:
Kleoniki Apostolidou, Eleni Zografos, Maria Alkistis Papatheodoridi, Oraianthi Fiste, Meletios Athanasios Dimopoulos, Flora Zagouri
Publikováno v:
Breast, Vol 75, Iss , Pp 103729- (2024)
Over the past few decades, first-line therapy for treating advanced and metastatic HR+/HER2-breast cancer has transformed due to the introduction of adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitors (CDK 4/6i). However, there is
Externí odkaz:
https://doaj.org/article/ce90e0cb4b9b49d7893e454d50307df2
Autor:
Angeliki Andrikopoulou, Kleoniki Apostolidou, Spyridoula Chatzinikolaou, Garyfalia Bletsa, Eleni Zografos, Meletios-Athanasios Dimopoulos, Flora Zagouri
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Externí odkaz:
https://doaj.org/article/cda9e8f6e70b4703989e58b0575d2721
Autor:
Angeliki Andrikopoulou, Eleni Zografos, Kleoniki Apostolidou, Anastasios Kyriazoglou, Alksistis-Maria Papatheodoridi, Maria Kaparelou, Konstantinos Koutsoukos, Michalis Liontos, Meletios-Athanasios Dimopoulos, Flora Zagouri
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundGermline BRCA1/2 mutations are identified in 13-15% of ovarian cancers, while an additional 5-7% of ovarian cancers harbor somatic BRCA1/2 mutations. Beyond these mutations, germline or somatic aberrations in genes of the homologous recombi
Externí odkaz:
https://doaj.org/article/ad7a03d06b4e42429fb6213aad41062c
Autor:
Angeliki Andrikopoulou, Kleoniki Apostolidou, Spyridoula Chatzinikolaou, Garyfalia Bletsa, Eleni Zografos, Meletios-Athanasios Dimopoulos, Flora Zagouri
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Over than one third (28–58%) of pregnancy-associated breast cancer (PABC) cases are characterized by positive epidermal growth factor receptor 2-positive (HER2) expression. Trastuzumab anti-HER2 monoclonal antibody is still the
Externí odkaz:
https://doaj.org/article/3da50813d03b4e3b892f62e033acd902
Autor:
Angeliki Andrikopoulou, Oraianthi Fiste, Kleoniki Apostolidou, Efthymia Skafida, Christos Markellos, Michalis Liontos, Anastasios Kyriazoglou, Meletios-Athanasios Dimopoulos, Flora Zagouri
Publikováno v:
Medical Sciences, Vol 9, Iss 2, p 42 (2021)
Background: Aromatase inhibitors (AIs) are associated with musculoskeletal pain in one third (20–47%) of breast cancer patients. Recently, CDK4/6 inhibitors have emerged as a new therapeutic approach in hormone receptor (HR)-positive breast cancer.
Externí odkaz:
https://doaj.org/article/b72bcc53044e41cf8c700e7f52164f57
Autor:
Efthymia Skafida, Meletios-Athanasios Dimopoulos, Kleoniki Apostolidou, Angeliki Rouvalis, Garyfallia Bletsa, Maria Kaparelou, Angeliki Andrikopoulou, F. Zagouri, Konstantinos Koutsoukos, Michalis Liontos
Publikováno v:
International Journal of Gynecologic Cancer. 33:571-576
Background: Immune checkpoint inhibitors (ICIs) have been widely implemented in the treatment of solid tumors. Although epithelial ovarian carcinoma is considered as scarcely immunogenic, the presence of tumor-infiltrating T lymphocytes (TILs) in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acdf88446b44bfb4d67887d0ab79cf0c
https://doi.org/10.1136/ijgc-2022-003941
https://doi.org/10.1136/ijgc-2022-003941
Autor:
Liontos, Angeliki Andrikopoulou, Charalampos Theofanakis, Christos Markellos, Maria Kaparelou, Konstantinos Koutsoukos, Kleoniki Apostolidou, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Meletios-Athanasios Dimopoulos, Flora Zagouri, Michalis
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3519
Background: There is limited data on the optimal time interval between the last dose of neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) in high-grade serous ovarian carcinoma (HGSC). Methods: We retrospectively identified patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::ee13d6db1128774544b6fbcb326d8db8
Autor:
ANASTASIOS KYRIAZOGLOU, ANNA-MARIA KORAKITI, ALKISTIS-MARIA PAPATHEODORIDI, KLEONIKI APOSTOLIDOU, AFRODITI NONNI, ELENI ZOGRAFOS, GARYFALIA BLETSA, DIMITRIS TSAKOGIANNIS, MELETIOS-ATHANASIOS DIMOPOULOS, FLORA ZAGOURI
Publikováno v:
In Vivo
Background/Aim: The Hippo pathway is a molecular pathway recently associated with tumorigenesis, metastasis, and drug resistance. Pregnancy-associated breast cancer (PABC) is the most common malignancy diagnosed during gestation; however, the molecul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de73800b884af102875b3196dffc38b9
https://doi.org/10.21873/invivo.13027
https://doi.org/10.21873/invivo.13027
Autor:
Maria Gavriatopoulou, Angeliki Andrikopoulou, Meletios-Athanasios Dimopoulos, Kleoniki Apostolidou, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Flora Zagouri, Spyridoula Chatzinikolaou
Publikováno v:
Oncotarget
Background Tumor protein 53 (TP53) gene mutations are identified in up to 37% of breast tumors especially in HER-2 positive and basal-like subtype. Previous studies have indicated TP53 mutations as a prognostic biomarker in breast cancer. However, mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e121dee1d547ea52dd12e98e8afdc118
https://doi.org/10.18632/oncotarget.28071
https://doi.org/10.18632/oncotarget.28071
Autor:
Angeliki Andrikopoulou, Michalis Liontos, Kleoniki Apostolidou, Charalampos Theofanakis, Christos Markellos, Oraianthi Fiste, Maria Kaparelou, Konstantinos Koutsoukos, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Meletios-Athanasios Dimopoulos, Flora Zagouri
BACKGROUND There is limited data on the optimal time interval between the last dose of neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS) in high-grade serous ovarian carcinoma (HGSC). METHODS We retrospectively identified patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1120e5034a7caa5ea5c978c4c015db07
https://doi.org/10.21203/rs.3.rs-2170155/v1
https://doi.org/10.21203/rs.3.rs-2170155/v1
